References

  1. 1.Menashe V. Heart murmurs. Pediatr Rev. 2007;28(4):e19-e22.
  2. 2.Campbell RM, Douglas PS, Eidem BW, et al. ACC/AAP/AHA/HRS/SCAI/SCCT/SCMR/SOPE 2014 appropriate use criteria for initial transthoracic echocardiography in outpatient pediatric cardiology: a report of the American College of Cardiology Appropriate Use Criteria Task Force, American Academy of Pediatrics, American Heart Association, American Society of Echocardiography, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, and Society of Pediatric Echocardiography. J Am Coll Cardiol. 2014;64(19):2039-2060.
  3. 3.Marelli AJ, Mackie AS, Ionescu-Ittu R, et al. Congenital heart disease in the general population: changing prevalence and age distribution. Circulation. 2007;115(2):163-172.
  4. 4.Ferencz C, Rubin JD, Loffredo CA, et al, eds. The Epidemiology of Congenital Heart Disease, The Baltimore-Washington Infant Study (1981-1989). Perspectives in Pediatric Cardiology. Vol 4. Futura Publishing; 1993.
  5. 5.Friedman S, Robie WA, Harris TN. Occurrence of innocent adventitious cardiac sounds in childhood. Pediatrics. 1949;4(6):782-789.
  6. 6.Smythe JF, Teixeira OH, Vlad P, et al. Initial evaluation of heart murmurs: are laboratory tests necessary? Pediatrics. 1990;86(4):497-500.
  7. 7.Ford B, Sebastian L. Heart murmurs in children: evaluation and management. Am Fam Physician. 2022;105(2):251-261.
  8. 8.Sapin SO. Recognizing normal heart murmurs: a logic-based mnemonic. Pediatrics. 1997;99(4):616-619.
  9. 9.Drezner JA, Sharma S, Baggish A, et al. International criteria for electrocardiographic interpretation in athletes: Consensus statement. Br J Sports Med. 2017;51(9):704-731.
  10. 10.Maron BJ, Towbin JA, Thiene G, et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association scientific statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation. 2006;113(14):1807-1816.
  11. 11.Kang SL, Benson L. Recent advances in cardiac catheterization for congenital heart disease. F1000 Res. 2018;7:370.
  12. 12.Park MK, Salamat M. Park’s Pediatric Cardiology for Practitioners. 7th ed. Elsevier; 2021.
  13. 13.Barstow CH. Congenital Heart Disease: Diagnosis. FP Essent. 2010;369:13-20.
  14. 14.Fixler DE, Pastor P, Chamberlin M, et al. Trends in congenital heart disease in Dallas County births. 1971-1984. Circulation. 1990;81(1):137-142.
  15. 15.Jenkins KJ, Correa A, Feinstein JA, et al. Noninherited risk factors and congenital cardiovascular defects: current knowledge: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young: endorsed by the American Academy of Pediatrics. Circulation. 2007;115(23):2995-3014.
  16. 16.Mahle WT, Newburger JW, Matherne GP, et al. Role of pulse oximetry in examining newborns for congenital heart disease: a scientific statement from the American Heart Association and American Academy of Pediatrics. Circulation. 2009;120(5):447-458.
  17. 17.Wong SF, Chan FY, Cincotta RB, et al. Factors influencing the prenatal detection of structural congenital heart diseases. Ultrasound Obstet Gynecol. 2003;21(1):19-25.
  18. 18.Gottliebson WM, Border WL, Franklin CM, et al. Accuracy of fetal echocardiography: a cardiac segment-specific analysis. Ultrasound Obstet Gynecol. 2006;28(1):15-21.
  19. 19.Koppel RI, Druschel CM, Carter T, et al. Effectiveness of pulse oximetry screening for congenital heart disease in asymptomatic newborns. Pediatrics. 2003;111(3):451-455.
  20. 20.Kemper AR, Mahle WT, Martin GR, et al. Strategies for implementing screening for critical congenital heart disease. Pediatrics. 2011;128(5):e1259-e1267.
  21. 21.Ilina MV, Kepron CA, Taylor GP, et al. Undiagnosed heart disease leading to sudden unexpected death in childhood: a retrospective study. Pediatrics. 2011;128(3):e513-e520.
  22. 22.Harris JP. Consultation with the specialist. Evaluation of heart murmurs. Pediatr Rev. 1994;15(12):490-494.
  23. 23.Malhotra A, Dhutia H, Finocchiaro G, et al. Outcomes of cardiac screening in adolescent soccer players. N Engl J Med. 2018;379(6):524-534.
  24. 24.Bar-Dayan Y, Elishkevits K, Goldstein L, et al. The prevalence of common cardiovascular diseases among 17-year-old Israeli conscripts. Cardiology. 2005;104(1):6-9.
  25. 25.Pang J, Bao Y, Mitchell-Silbaugh K, et al. Barth syndrome cardiomyopathy: an update. Genes (Basel). 2022;13(4):656.
  26. 26.Mordi I, Tzemos N. Bicuspid aortic valve disease: a comprehensive review. Cardiol Res Pract. 2012;2012:196037.
  27. 27.Marienfeld CJ, Telles N, Silvera J, et al. A 20-year follow-up study of “innocent” murmurs. Pediatrics. 1962;30(1):42-48.
  28. 28.Wen J, Snyder C. Prevalence of innocent murmurs in pediatric patients. Pediatrics. 2019;144(2 meeting abstract):325.
  1. 1.Bernhardt DT, Roberts WO, eds. PPE: Preparticipation Physical Evaluation. American Academy of Pediatrics; 2019.
  2. 2.Maron BJ, Thompson PD, Ackerman MJ, et al. Recommendations and considerations related to preparticipation screening for cardiovascular abnormalities in competitive athletes: 2007 update: a scientific statement from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. Circulation. 2007;115(12):1643-1655.
  3. 3.Williams EA, Pelto HF, Toresdahl BG, et al. Performance of the American Heart Association (AHA) 14-point evaluation versus electrocardiography for the cardiovascular screening of high school athletes: a prospective study. J Am Heart Assoc. 2019;8(14):e012235.
  4. 4.Riebe D, Franklin BA, Thompson PD, et al. Updating ACSM’s recommendations for exercise preparticipation health screening. Med Sci Sports Exerc. 2015;47(11):2473-2479.
  5. 5.Drezner JA, Sharma S, Baggish A, et al. International criteria for electrocardiographic interpretation in athletes: consensus statement. Br J Sports Med. 2017;51(9):704-731.
  6. 6.Van Camp SP, Bloor CM, Mueller FO, et al. Nontraumatic sports death in high school and college athletes. Med Sci Sports Exerc. 1995;27(5):641-647.
  7. 7.Malhotra A, Dhutia H, Finocchiaro G, et al. Outcomes in cardiac screening in adolescent soccer players. N Engl J Med. 2018;379(6):524-534.
  8. 8.La Gerche A, Wasfy MM, Brosnan MJ, et al. The athlete’s heart-challenges and controversies: JACC Focus Seminar 4/4. J Am Coll Cardiol. 2022;80(14):1346-1362.
  9. 9.Gerein RB, Osmond MH, Stiell IG, et al. What are the etiology and epidemiology of out-of-hospital pediatric cardiopulmonary arrest in Ontario, Canada? Acad Emerg Med. 2006;13(6):653-658.
  10. 10.Drezner JA, Chun JSDY, Harmon KG, et al. Survival trends in the United States following exercise-related sudden cardiac arrest in the youth: 2000-2006. Heart Rhythm. 2008;5(6):794-799.
  11. 11.Eckart RE, Shry EA, Burke AP, et al. Sudden death in young adults: an autopsy-based series of a population undergoing active surveillance. J Am Coll Cardiol. 2011;58(12):1254-1261.
  12. 12.Maron BJ, Doerer JJ, Haas TS, et al. Sudden deaths in young competitive athletes: analysis of 1866 deaths in the United States, 1980-2006. Circulation. 2009;119(8):1085-1092.
  13. 13.Bagnall RD, Weintraub RG, Ingles J, et al. A prospective study of sudden cardiac death among children and young adults. N Engl J Med. 2016;374(25):2441-2452.
  14. 14.Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2011;58(25):e212-e260.
  15. 15.Cirino AL, Ho C. Hypertrophic Cardiomyopathy Overview. GeneReviews. 2008.
  16. 16.Maron BJ, Maron MS. Hypertrophic cardiomyopathy. Lancet. 2013;381(9862):242-255.
  17. 17.Silka MJ, Shah MJ, Silva JNA, et al. 2021 PACES expert consensus statement on the indications and management of cardiovascular implantable electronic devices in pediatric patients: executive summary. Heart Rhythm. 2021;18(11):1925-1950.
  18. 18.Maron BJ, Udelson JE, Bonow RO, et al. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: Task Force 3: hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy and other cardiomyopathies, and myocarditis: a scientific statement from the American Heart Association and American College of Cardiology. J Am Coll Cardiol. 2015;66(21):2362-2371.
  19. 19.Gaudino M, Di Franco A, Arbustini E, et al. Management of adults with anomalous aortic origin of the coronary arteries: state of the art review. J Am Coll Cardiol. 2023;82(21):2034-2053.
  20. 20.Basso C, Maron BJ, Corrado D, Thiene G. Clinical profile of congenital coronary artery anomalies with origin from the wrong aortic sinus leading to sudden death in young competitive athletes. J Am Coll Cardiol. 2000;35(6):1493-1501.
  21. 21.Van Hare GF, Ackerman MJ, Evangelista JK, et al. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: Task Force 4: congenital heart disease. J Am Coll Cardiol. 2015;66(21):2372-2384.
  22. 22.Gauer RL, Guess JM, Criswell W. Cardiovascular Disease: Inflammatory and Infectious Heart Conditions. FP Essent. 2024;536:29-45.
  23. 23.Corrado D, Basso C, Thiene G. Arrhythmogenic right ventricular cardiomyopathy: diagnosis, prognosis, and treatment. Heart. 2000;83(5):588-595.
  24. 24.Calò L, Oliviero G, Crescenzi C, et al. Electrocardiogram in arrhytmogenic cardiomyopathy. Eur Heart J Suppl. 2023;25(Suppl C):C169-C172.
  25. 25.Corrado D, Zorzi A, Cipriani A, et al. Evolving diagnostic criteria for arrhythmogenic cardiomyopathy. J Am Heart Assoc. 2021;10(18):e021987.
  26. 26.Chabra L, Goyal A, Benham MD. Wolf-Parkinson-White syndrome. StatPearls. 2023.
  27. 27.Loeys BL, Dietz HC, Braverman AC, et al. The revised Ghent nosology for the Marfan syndrome. J Med Genet. 2010;47(7):476-485.
  28. 28.Ackerman MJ, Zipes DP, Kovacs RJ, et al. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: Task Force 10: the cardiac channelopathies: a scientific statement from the American Heart Association and American College of Cardiology. Circulation. 2015;132(22):e326-e329.
  1. 1.Brugada J, Blom N, Sarquella-Brugada G, et al. Pharmacological and non-pharmacological therapy for arrhythmias in the pediatric population: EHRA and AEPC-Arrhythmia Working Group joint consensus statement. Europace. 2013;15(9):1337-1382.
  2. 2.Borquez AA, Williams MR. Essentials of paroxysmal supraventricular tachycardia for the pediatrician. Pediatr Ann. 2021;50(3):e113-e120.
  3. 3.Blaufox AD, Rhodes JF, Fishberger SB. Age related changes in dual AV nodal physiology. Pacing Clin Electrophysiol. 2000;23(4 Pt 1):477-480.
  4. 4.Perry JC, Garson A. Supraventricular tachycardia due to Wolff-Parkinson-White syndrome in children: early disappearance and late recurrence. J Am Coll Cardiol. 1990;16(5):1215-1220.
  5. 5.Zipes DP, Link MS, Ackerman MJ, et al. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: Task Force 9: arrhythmias and conduction defects: a statement from the American Heart Association and American College of Cardiology. Circulation. 2015;132(22):e315-e325.
  6. 6.Strasburger JF, Eckstein G, Butler M, et al. Fetal arrhythmia diagnosis and pharmacological management. J Clin Pharmacol. 2022;62(Suppl 1):S53-S66.
  7. 7.Heinzmann-Filho JP, Zanatta LB, Vendrusculo FM, et al. Maximum heart rate measured versus estimated by different equations during the cardiopulmonary exercise test in obese adolescents. Rev Paul Pediatr. 2018;36(3):309-314.
  8. 8.Chabra L, Goyal A, Benham MD. Wolf-Parkinson-White syndrome. StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK554437
  9. 9.Khaznadar R, Chandler SF, Chaouki AS, et al. Non-invasive risk stratification in pediatric ventricular pre-excitation. Pediatr Cardiol. 2020;41(4):709-715.
  10. 10.Sanatani S, Hamilton RM, Gross GJ. Predictors of refractory tachycardia in infants with supraventricular tachycardia. Pediatr Cardiol. 2002;23(5):508-512.
  11. 11.Dubin AM, Jorgensen NW, Radbill AE, et al. What have we learned in the last 20 years? A comparison of a modern era pediatric and congenital catheter ablation registry to previous pediatric ablation registries. Heart Rhythm. 2019;16(1):57-63.
  12. 12.Wilde AAM, Amin AS, Postema PG. Diagnosis, management and therapeutic strategies for congenital long QT syndrome. Heart. 2022;108(5):332-338.
  13. 13.Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, and the Heart Rhythm Society. Circulation. 2018;138(13):e272-e391.
  14. 14.Galić E, Bešlić P, Kilić P, et al. Congenital long QT syndrome: a systematic review. Acta Clin Croat. 2021;60(4):739-748.
  15. 15.Silka MJ, Shah MJ, Silva JNA, et al. 2021 PACES expert consensus statement on the indicators and management of cardiovascular implantable electronic devices in pediatric patients: executive summary. Heart Rhythm. 2021;18(11):1925-1950.
  16. 16.Olde Nordkamp LRA, Postema PG, Knops RE, et al. Implantable cardioverter-defibrillator harm in young patients with inherited arrhythmia syndromes: a systematic review and meta-analysis of inappropriate shocks and complications. Heart Rhythm. 2016;13(2):443-454.
  17. 17.Ataíde Silva R, Sousa AR, de Carvalho MSL, et al. Congenital long QT syndrome presenting as unexplained bradycardia. BMJ Case Rep. 2022;15(3):e242362.
  18. 18.Villain E, Levy M, Kachaner J, et al. Prolonged QT interval in neonates: benign, transient, or prolonged risk of sudden death. Am Heart J. 1992;124(1):194-197.
  19. 19.Credible Meds. Congenital LQT and Drugs to Avoid. https://crediblemeds.org
  20. 20.Steinberg L. Congenital heart block. Cardiol Clin. 2023;41(3):399-410.
  21. 21.Ambrosi A, Sonesson SE, Wahren-Herlenius M. Molecular mechanisms of congenital heart block. Exp Cell Res. 2014;325(1):2-9.
  22. 22.Park MK. Cardiac arrhythmias. In: Pediatric Cardiology for Practitioners. 5th ed. Mosby Elsevier; 2007:434-436.
  1. 1.McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation. 2017;135(17):e927-e999.
  2. 2.Holman RC, Belay ED, Christensen KY, et al. Hospitalizations for Kawasaki syndrome among children in the United States, 1997-2007. Pediatr Infect Dis J. 2010;29(6):483-488.
  3. 3.Morens DM, Anderson LJ, Hurwitz ES. National surveillance of Kawasaki disease. Pediatrics. 1980;65(1):21-25.
  4. 4.Rodó X, Ballester J, Cayan D, et al. Association of Kawasaki disease with tropospheric wind patterns. Sci Rep. 2011;1:152.
  5. 5.Kawasaki Disease Foundation. The symptoms of Kawasaki disease. https://kdfoundation.org/kd-symptoms/
  6. 6.Kanegaye JT, Wilder MS, Molkara D, et al. Recognition of a Kawasaki disease shock syndrome. Pediatrics. 2009;123(5):e783-e789.
  7. 7.Kao CH, Hsieh KS, Wang YL, et al. The detection of ventricular dysfunction and carditis in children with Kawasaki disease using equilibrium multigated blood pooling ventriculography and 99Tcm-HMPAO-labelled WBC heart scans. Nucl Med Commun. 1993;14(7):539-543.
  8. 8.Newburger JW, Takahashi M, Burns JC, et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med. 1986;315(6):341-347.
  9. 9.Printz BF, Sleeper LA, Newburger JW, et al. Noncoronary cardiac abnormalities are associated with coronary artery dilation and with laboratory inflammatory markers in acute Kawasaki disease. J Am Coll Cardiol. 2011;57(1):86-92.
  10. 10.Baumer JH, Love SJ, Gupta A, et al. Salicylate for the treatment of Kawasaki disease in children. Cochrane Database Syst Rev. 2006(4):CD004175.
  11. 11.Jonat B, Geneslaw AS, Capone CA, et al. Early treatment of multisystem inflammatory syndrome in children. Pediatrics. 2023;152(3):e2023061297.
  12. 12.Starnes LS, Starnes J, Stopczynski T, et al. Clinical prediction model: multisystem inflammatory syndrome in children versus Kawasaki disease. J Hosp Med. 2024;19(3):175-184.
  13. 13.Henderson LA, Canna SW, Friedman KG, et al. American College of Rheumatology clinical guidance for multisystem inflammatory syndrome in children associated with SARS-CoV-2 and hyperinflammation in pediatric COVID-19: Version 3. Arthritis Rheumatol. 2022;74(4):e1-e20.
  14. 14.Centers for Disease Control and Prevention. Case definitions and reporting. Multisystem inflammatory syndrome in children associated with SARS-CoV-2 infection. https://www.cdc.gov/mis/hcp/case-definition-reporting/index.html
  15. 15.Feldstein LR, Tenforde MW, Friedman KG, et al. Characteristics and outcomes of children and adolescents with multisystem inflammatory syndrome in children (MIS-C) compared with severe acute COVID-19. JAMA. 2021;325(11):1074-1087.
  16. 16.Dionne A, Mah DY, Son MBF, et al. Atrioventricular block in children with multisystem inflammatory syndrome. Pediatrics. 2020;146(5):e2020009704.
  17. 17.Gluckman TJ, Bhave NM, Allen LA. at al. 2022 ACC expert consensus decision pathway on cardiovascular sequelae of COVID-19 in adults: myocarditis and other myocardial involvement, post sequelae of SARS-CoV-2 infection, and return to play. J Am Coll Cardiol. 2022;79(17):1717-1756.
  18. 18.Edwards S, Small JD, Geratz JD, et al. An experimental model for myocarditis and congestive heart failure after rabbit coronavirus infection. J Infect Dis. 1992;165(1):134-140.
  19. 19.Alexander LK, Small JD, Edwards S, et al. An experimental model for dilated cardiomyopathy after rabbit coronavirus infection. J Infect Dis. 1992;166(5):978-985.
  20. 20.Centers for Disease Control and Prevention. Coronavirus disease 2019 (COVID-19) vaccine safety. https://www.cdc.gov/vaccine-safety/vaccines/covid-19.html
  21. 21.Tuvali O, Tshori S, Derazne E, et al. The incidence of myocarditis and pericarditis in post COVID-19 unvaccinated patients—a large population-based study. J Clin Med. 2022;11(8):2219.
  22. 22.Gauer RL, Guess JM. Cardiovascular Disease: Inflammatory and Infectious Heart Conditions. FP Essent. 2024;536:29-45.
  23. 23.Daniels CJ, Rajpal S, Greenshields JT, et al. Prevalence of clinical and subclinical myocarditis in competitive athletes with recent SARS-CoV-2 Infection. JAMA Cardiol. 2021;6(9):1078-1087.
  24. 24.Kuruvilla S, Adenaw N, Katwal AB, et al. Late gadolinium enhancement on cardiac magnetic resonance predicts adverse cardiovascular outcomes in nonischemic cardiomyopathy: a systematic review and meta-analysis. Circ Cardiovasc Imaging. 2014;7(2):250-258.
  25. 25.Boehmer TK, Kompaniyets L, Lavery AM, et al. Association between COVID-19 and myocarditis using hospital-based administrative date–United States, March 2020-January 2021. MMWR Morb Mortal Wkly Rep. 2021;70(35):1228-1232.
  26. 26.Lin YC, Chang CH, Su WJ, et al. Risk of coronavirus disease 2019 messenger RNA vaccination-associated myocarditis and pericarditis—a systematic review of population-based data. Risk Manag Healthc Policy. 2023;16:2085-2099.
  27. 27.Mevorach D, Anis E, Cedar N, et al. Myocarditis after BNT162b2 mRNA vaccine against COVID-19 in Israel. N Engl J Med. 2021;385(23):2140-2149.
  28. 28.Oster ME, Shay DK, Su JR, et al. Myocarditis cases reported after mRNA-based COVID-19 vaccination in the US from December 2020 to August 2021. JAMA. 2022;327(4):331-340.
  29. 29.Karlstad Ø, Hovi P, Husby A, et al. SARS-CoV-2 vaccination and myocarditis in a Nordic cohort study of 23 million residents. JAMA Cardiol. 2022;7(6):600-612.
  30. 30.Mahasing C, Doungngern P, Jaipong R, et al. Myocarditis and pericarditis following COVID-19 vaccination in Thailand. Vaccines (Basel). 2023;11(4):749.
  31. 31.Mansanguan S, Charunwatthana P, Piyaphanee W, et al. Cardiovascular manifestation of the BNT162b2 mRNA COVID-19 vaccine in adolescents. Trop Med Infect Dis. 2022;7(8):196.
  32. 32.Buergin N, Lopez-Ayala P, Hirsiger JR, et al. Sex-specific differences in myocardial injury incidence after COVID-19 mRNA-1273 booster vaccination. Eur J Heart Fail. 2023;25(10):1871-1881.
  33. 33.Jain E, Donowitz JR, Aarons E, et al. Multisystem inflammatory syndrome in children after SARS-CoV2 vaccination. Emerg Infect Dis. 2022;28(5):990-993.
  34. 34.Levy M, Recher M, Hubert H, et al. Multisystem inflammatory syndrome in children by COVID-19 vaccination status of adolescents in France. JAMA. 2022;327(3):281-283.

Current edition

Hepatitis Overview

Hepatitis Overview

Copyright © 2026 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. See permissions for copyright questions and/or permission requests.